- Home
- EQ vs BRNS Comparison
EQ vs BRNS Comparison
Compare EQ & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- BRNS
- Stock Information
- Founded
- EQ 2017
- BRNS 2016
- Country
- EQ United States
- BRNS United Kingdom
- Employees
- EQ N/A
- BRNS N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- EQ Health Care
- BRNS Health Care
- Exchange
- EQ Nasdaq
- BRNS Nasdaq
- Market Cap
- EQ 57.8M
- BRNS 55.9M
- IPO Year
- EQ 2018
- BRNS 2021
- Fundamental
- Price
- EQ $1.00
- BRNS $0.70
- Analyst Decision
- EQ Hold
- BRNS Strong Buy
- Analyst Count
- EQ 1
- BRNS 1
- Target Price
- EQ $1.00
- BRNS $4.00
- AVG Volume (30 Days)
- EQ 395.1K
- BRNS 134.6K
- Earning Date
- EQ 11-13-2025
- BRNS 11-07-2025
- Dividend Yield
- EQ N/A
- BRNS N/A
- EPS Growth
- EQ N/A
- BRNS N/A
- EPS
- EQ N/A
- BRNS N/A
- Revenue
- EQ $4,392,000.00
- BRNS N/A
- Revenue This Year
- EQ N/A
- BRNS N/A
- Revenue Next Year
- EQ N/A
- BRNS N/A
- P/E Ratio
- EQ N/A
- BRNS N/A
- Revenue Growth
- EQ N/A
- BRNS 1766.46
- 52 Week Low
- EQ $0.27
- BRNS $0.64
- 52 Week High
- EQ $2.35
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- EQ 39.57
- BRNS 24.24
- Support Level
- EQ $0.98
- BRNS $0.75
- Resistance Level
- EQ $1.16
- BRNS $0.81
- Average True Range (ATR)
- EQ 0.14
- BRNS 0.11
- MACD
- EQ -0.02
- BRNS -0.04
- Stochastic Oscillator
- EQ 30.20
- BRNS 1.49
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.